

Editorial

Stabilization versus Ablation of Tumor Vasculature: Implications in Radio and Chemo-Sensitization

Mahmoud AM^{1,2*} and Ali MM¹

¹Department of Kinesiology and Nutrition, University of Illinois at Chicago, USA

²Department of Pathology, South Egypt Cancer Institute, Egypt

*Corresponding author: Abeer M. Mahmoud, Department of Kinesiology and Nutrition, College of Applied Health Sciences, University of Illinois at Chicago, Chicago, IL, USA

Received: June 01, 2016; Accepted: June 02, 2016;

Published: June 03, 2016

Editorial

It is well established that tumors are unable to grow beyond certain size (1-2 mm) unless they acquire their own blood supply *via* angiogenesis. In addition, angiogenesis helps tumors to invade adjacent tissues and metastasize to distant sites. Therefore, it has been postulated that interfering with the blood supply using anti-angiogenic therapies will destroy the tumor. However, there is an emerging alternative concept that depriving the tumor of its blood supply interferes with the delivery of chemotherapeutic agents to the tumor and creates unfavorable hypoxic environment that compromises the action of radiotherapy. This concept was supported by the modest responses to anti-angiogenic therapies in clinical trials and the lack of any impact on patient's survival when antiangiogenic drugs are administered as single agents [1]. Although, Hurwitz, *et al* [2] have shown that combining the antiangiogenic drug, Bevacizumab with chemotherapy significantly improved survival among metastatic colorectal cancer patients. Still, other studies demonstrated reductions in tumor concentrations of chemotherapy or effectiveness of radiotherapy when antiangiogenic drugs were co-administered [3-5]. Even when antiangiogenic drugs yielded significant effects on the growth of some tumors such as renal cell carcinoma, cervical cancer and ovarian cancer, they failed to demonstrate significant improvements in patients' survival [6,7]. Furthermore, complete resistance to antiangiogenic therapies have been reported for prostate and pancreatic adenocarcinoma and melanoma [8,9]. In order to explain this inconsistency, further research is needed for better understanding of the underlying cellular and molecular mechanisms of tumor vascularization and its interaction with cancer therapies in different tumor beds.

Tumors' blood vessels are often larger and more conspicuous than those of normal tissues [10]. However, tumors tend to actually have less blood supply than normal tissues because tumor blood vessels are fragile, leaky, morphologically abnormal and malfunctioning [11,12]. While the normal vasculature consists of evenly spaced, well-differentiated arteries, arterioles, capillaries, venules and veins, the tumor vasculature is heterogeneous, unevenly distributed and chaotic with a tortuous irregular course that leads to zones of

hypoxia and acidosis [13]. Tumors initiate a vascular supply through secreting angiogenic factors, mainly Vascular Endothelial Growth Factor (VEGF) [14]. Despite being of critical value in controlling the physiological processes of angiogenesis and vascular permeability [15], when continuously over-expressed in tumor tissues, VEGF induces accelerated and defective angiogenesis wherein vessels are immature, leaky, tortuous and characterized by defective anatomy and physiology [16]. These structural abnormalities contribute to spatial and temporal heterogeneity in tumor blood function, resulting in poorly perfused and subsequently hypoxic tumor microenvironment. Targeting tumor vessels *via* Anti-VEGF/VEGFR drugs have not been effective as a cure since impeding tumor blood supply deprives the tumor of oxygen, leading to hypoxia and acidosis that, in turn, can promote tumor growth, abnormal angiogenesis, and metastasis and also compromise the cytotoxic functions of immune cells that infiltrate tumors [17]. In addition, reduced tumor vascularity is a main contributor to therapeutic resistance in cancer since it interferes with the delivery of anti-cancer agents to the tumor targeted by chemotherapy or minimizes the production of Reactive Oxygen Species (ROS) in the tumor area, which is essential for radiation therapy induced cell killing [18,19]. Radiation-induced effects on cancer are brought about by inducing ROS production, DNA damage and apoptosis [20]. However, poor vascularization and hypoxia that characterize solid tumors induce resistance to radiotherapy and are positively correlated with more invasion and metastasis. This is achieved by two mechanisms: first, through the lack of O₂ and hence the interference with radiation-induced ROS production. Second, *via* the hypoxia inducible factor-1 α (HIF-1 α) that provokes adaptive intracellular responses that, in turn, facilitate cell proliferation, interfere with apoptosis, provide protection from cell demise and ultimately rendering tumors radioresistant [21]. As a result, increasing the chemotherapeutic doses or strategies to intensify radiotherapy have been employed to increase the treatment efficacy. However, these procedures can potentially lead to a higher risk of serious side effects. To raise the therapeutic ratio (the ratio between the desirable cytotoxic effects and normal tissue complications), new strategies to enhance chemo and radiosensitivity of cancer are needed. To this end, we need to develop methods to improve tumor blood perfusion and normalize vascular development in order to increase tumor vulnerability to anti-cancer therapy as a better alternative to starving a tumor of its blood supply, which is not curative. Furthermore, one needs to emphasize that antiangiogenic drugs are not without side effects. Indeed, they have been reported to induce a myriad of toxic effects such as hypertension, hemorrhage, thromboembolism, proteinuria, malaise, fatigue, biochemical hypothyroidism, and cardiac failure, all are related to the non-specific action of antiangiogenic drugs that affects both normal and cancer tissues [1].

Tumor vasculature is functionally different than normal tissues'

blood vessels. It is not simply the copious blood perfusion that induces tumor growth. Rather, enhanced tumor growth occurs in response to nurturing molecules produced by tumor-associated endothelial cells such as the unbalanced production of VEGF(s). However, due to the non-specificity of the current anti-VEGF/VEGFR drugs and the treatment-resistant hypoxic environment subsequent to depriving the tumor of its blood supply, discovering new therapeutic targets in the tumor-associated endothelial cells is warranted. Recently, Notch receptor and its ligand Jagged-1 have been identified as key regulators of tumor angiogenesis. Studies on blocking notch and Jagged-1 signaling demonstrated tumor growth inhibition however this was accompanied by an increase in the number of non-functional vessels and poor tumor perfusion [22]. Thus, it is conceivable that ideal targets would be molecules or growth factors that are produced only by tumor-associated endothelial cells that can be blocked in order to normalize tumor vasculature without obstructing tumor blood supply, altering oxygen delivery or sheltering the tumor from chemotherapy.

In addition to over expressing tumor growth promoting factors, tumor-associated endothelial cells lack specific protein complexes that connect endothelial cells together such as the vascular endothelial adhesion molecule, VE-cadherin [23]. Alteration in these complexes causes leakage of fluid and molecules out of the vessels resulting in edema and hampers the delivery of cancer therapy to the tumor tissue which, in turn, contributes to cancer therapeutic resistance. Therefore, restoring VE-cadherin or other endothelial cell adhesion molecules in tumor-associated blood vessels could be a promising target for vascular normalization in cancer therapies. Besides direct targeting of angiogenic factors, an alternative recent approach involves modification of epigenetic processes. An emerging evidence supports a role of histone deacetylation and DNA methylation in the regulation of angiogenesis. Accordingly, several Histone Deacetylase (HDAC) and DNA Methyltransferase (DNMT) inhibitors are being examined for their anti-angiogenic properties [24]. Also, a new group of microRNAs (miRs) involved in cancer-related aberrant angiogenesis, hypoxia and cancer metastasis has been recently discovered. These miRs are referred to as angiomiRs and hypoxamiRs and they stand as promising new therapeutic targets in cancer [25].

A new venue that we believe is worth exploration is physical exercise as a non-pharmacological novel adjuvant therapy to normalize tumor blood vessels, restore their normal structure and function and subsequently increase tumor sensitivity to cancer therapy. The foundation of this assumption comes from the strong epidemiological and experimental evidence supporting the role of exercise in improving blood flow and tissue perfusion in normal and post-ischemic tissues [26-29]. Exercise elevates the intravascular shear stress which in turn activates endothelial cell production of vasodilators [30]. A number of vasodilators have been shown to increase in response to exercise however, two compounds stand out as central mediators of exercise action: Nitric Oxide (NO) and Prostacyclin [31]. Exercise-induced vasodilation increases tissue hyperemia and oxygenation which subsequently normalizes the microenvironment and induces the formation of new well-developed, normal-functioning blood vessels. This pro-angiogenic effect of exercise has been proposed to be mediated through several angiogenic factors such as VEGF, angiopoietin 1 and 2, PPAR gamma

coactivator-1alpha, cAMP- and cGMP-independent smooth muscle relaxation [31-33]. Exercise has been shown to restore the balance between pro- and antiangiogenic factors which promotes a shift towards normalized tumor microenvironment.

Intriguingly, emerging data indicate that aerobic exercise improves tumor perfusion and cancer therapy efficacy and reduces tumor metastasis in preclinical prostate and breast cancer models [34-36]. In a prospective cohort of 571 men with prostate cancer, Van Blarigan, *et al* demonstrated that physical activity normalized tumor vessel density, size and shape [37]. Despite this progress in unraveling the effect of exercise in improving cancer perfusion and treatment sensitivity, we do not see exercise being recommended for cancer patients who are more likely to have complications that discourage them from exercising. Probably if more clinical trials succeeded to prove that exercise synergizes with cancer therapy, there would be a strong impetus for patients to exercise and for oncologists to recommend exercise for their patients.

In conclusion, it is imperative to understand the underpinnings of tumor vascularity and microenvironment. Tumor blood vessels, albeit malfunctioning, they are the portal to deliver drugs to cancer tissues thus, instead of targeting tumor vessels for elimination, functional enhancement might be tried instead. Identifying novel therapeutic targets and interventions to normalize tumor vascular bed should make it possible to enhance the efficacy of cancer chemo and radiotherapies.

References

- Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. *Lancet*. 2016.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *The New England Journal of Medicine*. 2004; 350: 2335-2342.
- Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. *Cancer Research*. 2001; 61: 5491-5498.
- Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. *International Journal of Radiation Oncology, biology, physics*. 1997; 37: 1107-1113.
- Fenton BM, Paoni SF, Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. *Radiotherapy and Oncology: Journal of the European Society of Radiology and Oncology*. 2004; 72: 221-230.
- Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, et al. Randomized phase III trial of tamsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2014; 32: 760-767.
- Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2016; 387: 1066-1074.
- Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, et al. Gemcitabine plus Bevacizumab compared with Gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2010; 28: 3617-3622.
- Michaelson MD, Oudard S, Ou YC, Sengelov L, Saad F, Houede N, et al.

- Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2014; 32: 76-82.
10. Dudley AC. Tumor endothelial cells. *Cold Spring Harbor Perspectives in Medicine*. 2012; 2: 006536.
 11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature*. 2000; 407: 249-257.
 12. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. *Current Opinion in Genetics & Development*. 2005; 15: 102-111.
 13. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explains tumor vessel leakiness. *The American Journal of Pathology*. 2000; 156: 1363-1380.
 14. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. *Cancer Research*. 1997; 57: 963-969.
 15. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. *Annual Review of Pathology*. 2007; 2: 251-275.
 16. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. *Angiogenesis*. 2008; 11: 109-119.
 17. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nature Clinical Practice Oncology*. 2006; 3: 24-40.
 18. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. *Nature*. 2003; 423: 593-595.
 19. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. *Nature Reviews Cancer*. 2008; 8: 180-192.
 20. Bromfield GP, Meng A, Warde P, Bristow RG. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. *Prostate Cancer and Prostatic Diseases*. 2003; 6: 73-85.
 21. Semenza GL. Targeting HIF-1 for cancer therapy. *Nature Reviews Cancer*. 2003; 3: 721-732.
 22. Sainson RC, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signaling in endothelial cells and pericytes: from basic research to potential therapies. *Angiogenesis*. 2008; 11: 41-51.
 23. Le Guelte A, Dwyer J, Gavard J. Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. *Biology of the cell / under the auspices of the European Cell Biology Organization*. 2011; 103: 593-605.
 24. Shiva Shankar TV, Willems L. Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network. *Vascular Pharmacology*. 2014; 60: 57-66.
 25. Matejuk A, Collet G, Nadim M, Grillon C, Kieda C. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. *Archivum Immunologiae et Therapiae Experimentalis*. 2013; 61: 285-299.
 26. Joyner MJ, Casey DP. Regulation of increased blood flow (hyperemia) to muscles during exercise: a hierarchy of competing physiological needs. *Physiological Reviews*. 2015; 95: 549-601.
 27. Ashor AW, Lara J, Siervo M, Celis-Morales C, Oggioni C, Jakovljevic DG, et al. Exercise modalities and endothelial function: a systematic review and dose-response meta-analysis of randomized controlled trials. *Sports Medicine*. 2015; 45: 279-296.
 28. Scott BR, Slattery KM, Sculley DV, Dascombe BJ. Hypoxia and resistance exercise: a comparison of localized and systemic methods. *Sports Medicine*. 2014; 44: 1037-1054.
 29. Koga S, Rossiter HB, Heinonen I, Musch TI, Poole DC. Dynamic heterogeneity of exercising muscle blood flow and O₂ utilization. *Medicine and Science in Sports and Exercise*. 2014; 46: 860-876.
 30. Rodriguez I, Gonzalez M. Physiological mechanisms of vascular response induced by shear stress and effect of exercise in systemic and placental circulation. *Frontiers in Pharmacology*. 2014; 5: 209.
 31. Hellsten Y, Nyberg M, Jensen LG, Mortensen SP. Vasodilator interactions in skeletal muscle blood flow regulation. *The Journal of Physiology*. 2012; 590: 6297-6305.
 32. Chinsomboon J, Ruas J, Gupta RK, Thom R, Shoag J, Rowe GC, et al. The transcriptional coactivator PGC-1alpha mediates exercise-induced angiogenesis in skeletal muscle. *Proceedings of the National Academy of Sciences of the United States of America*. 2009; 106: 21401-21406.
 33. Hoier B, Hellsten Y. Exercise-induced capillary growth in human skeletal muscle and the dynamics of VEGF. *Microcirculation*. 2014; 21: 301-314.
 34. Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, et al. Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. *Journal of Applied Physiology*. 2012; 113: 263-272.
 35. Betof AS, Lascola CD, Weitzel D, Landon C, Scarbrough PM, Devi GR, et al. Modulation of murine breast tumor vascularity, hypoxia and chemotherapeutic response by exercise. *Journal of the National Cancer Institute*. 2015; 107.
 36. McCullough DJ, Nguyen LM, Siemann DW, Behnke BJ. Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. *Journal of Applied Physiology*. 2013; 115: 1846-1854.
 37. Van Blarigan EL, Gerstenberger JP, Kenfield SA, Giovannucci EL, Stampfer MJ, Jones LW, et al. Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study. *Cancer Prevention Research*. 2015; 8: 962-967.